Medicover's India Moment: Growth, Leverage, and a Strategic Door

Q2 2026 delivers double-digit growth and margin expansion, but the real story is the potential sale of the India business.

MCOV-B.ST · Earnings Call · 2026-07-22

A Quarter of Progress

Medicover's Q2 2026 report was, in CEO John Stubbington's words, "a quarter of positive progression." Organic revenue grew 11.8%, adjusted EBITDA margin expanded to 17.1%, and operating cash flow jumped 28.4% to EUR 73.6 million. CFO Anand Patel highlighted the fee-for-service strength: “I'll describe the quarter as a solid quarter and consistency in us delivering double-digit organic growth from a revenue perspective and margin accretion as well.” — Anand Patel, CFO · 2026-07-22 The company also noted its sixth consecutive quarter of margin improvement, a feat made sweeter by a tough comparable base. But beneath the steady numbers lies a more consequential narrative: the future of Medicover's high-growth Indian business.

India: The Strategic Pivot

The Indian operation has been a recurring theme for Medicover, and the momentum is finally showing. Revenue in India grew 39.6% in local currency, up from 34.4% last quarter. This is the payoff from years of hiring doctors and opening hospitals. As Stubbington put it, “India, as I said before, a lot of conversation, a lot of talk about India if we go back 12 months, and we said that we would start to see the momentum of that coming through, and it is coming through.” — John Stubbington, CEO · 2026-07-22 The new hospital openings in India, including a 14-floor tower in Hyderabad, are the final planned expansions in the region. But the bigger signal came when an analyst asked about KKR's reported interest. Stubbington said:

Our responsibility, if somebody does that, is for us to evaluate things and see what's the best course of action for us.
John Stubbington, CEO · 2026-07-22

He reiterated that an IPO remains an option and that no decisions have been made. Still, the mere acknowledgment of third-party interest marks a shift from the prior stance. Just a quarter ago, management was focused on the IPO timeline; now they are explicitly weighing alternatives, and the revenue stream from India is becoming too attractive to ignore.

Fee-for-Service and the Reform Tailwind

Beyond India, the Reform in Germany and Poland continues to reshape the payer mix. Management emphasized that fee-for-service revenue is the core focus, and it's growing. The shift is deliberate: “We want to provide high-quality healthcare to the people that entrust their money with us” — John Stubbington, CEO · 2026-07-22 — and this philosophy is guiding price adjustments and portfolio decisions. In Diagnostics, organic growth of 10.9% was driven by both price and volume, with Germany's regulatory constraints making the achievement more notable. The company's leverage also moved in the right direction, down to 2.9x from 3.6x a year ago, and EBITDAaL margin expanded 50 bps to 11.3%. The improved cash generation gives Medicover optionality—whether to invest in expansion, return capital, or pursue strategic options like the potential India sale.

What's Next

The key question is whether Medicover's India business becomes a sale, an IPO, or remains a wholly-owned growth engine. The answer will likely reshape the company's profile. As Stubbington said in a prior call, “the momentum is a really key word when it comes to India” — John Stubbington, CEO · 2026-02-10 and back then, the expectation was to accelerate toward an IPO. Now, the door has opened wider. In an earlier call, he also noted, “We're at the business end of that.” — John Stubbington, Chief Executive Officer · 2025-11-05 The next few quarters will be telling.